<DOC>
	<DOCNO>NCT00089245</DOCNO>
	<brief_summary>The purpose study find safe dose new medicine call antibody 8H9 . Antibodies make body fight infection case , fight tumor . The antibody 8H9 make mouse attack many kind tumor . 8H9 antibody dose radiation attach call 131-I . 131I-8H9 give vein patient find cancer cell . This first study use 131I-8H9 fluid spine kill cancer cell . 131-I beta emit isotope use extensively radiation target therapy .</brief_summary>
	<brief_title>Radiolabeled Monoclonal Antibody Therapy Treating Patients With Refractory , Recurrent , Advanced CNS Leptomeningeal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Subject Patients must histologically confirm diagnosis malignancy know 8H9 reactive . 8H9 expression must confirm immunohistochemical stain tumor assess Department Pathology immunofluorescence bone marrow except patient confirm neuroblastoma . Patients must CNS/ leptomeningeal disease refractory conventional therapy conventional therapy exist OR recurrent brain tumor predilection leptomeningeal dissemination ( medulloblastoma , PNET , rhabdoid tumor ) . Patients must rapidly progress deteriorate neurologic examination . Patients must absolute neutrophil count ( ANC ) &gt; 1000/ul platelet count &gt; 50,000/ul . Patients may active malignancy outside central nervous system . Both pediatric adult patient age eligible . Patients legal guardian sign inform consent form approve IRB obtain Principal Co Investigator patient entry . Minors provide assent . Patients stored stem cell treat escalate dose patient stem cell treat 50 mCi dose . Neuroblastoma patient treat 50 mCi dose without stored stem cell . Subject Patients obstructive symptomatic communicating hydrocephalus . Patients uncontrolled lifethreatening infection . Patients pregnant : Pregnant woman exclude fear danger fetus . Therefore negative pregnancy test require woman childbearing age , appropriate contraception require study period . Patients receive cranial spinal irradiation le 3 week prior start protocol . Patients receive systemic chemotherapy ( corticosteroid include ) less 3 week prior start protocol . Severe major organ toxicity . Specifically , renal , cardiac , hepatic , pulmonary , gastrointestinal system toxicity less grade 2 . Patients stable neurological deficit ( brain tumor ) exclude . Patients &lt; = 3 hearing loss exclude .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>leptomeningeal metastasis</keyword>
	<keyword>recurrent neuroblastoma</keyword>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>recurrent childhood medulloblastoma</keyword>
	<keyword>recurrent childhood rhabdomyosarcoma</keyword>
	<keyword>recurrent childhood soft tissue sarcoma</keyword>
	<keyword>recurrent osteosarcoma</keyword>
	<keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>childhood atypical teratoid/rhabdoid tumor</keyword>
	<keyword>adult medulloblastoma</keyword>
	<keyword>previously treat childhood rhabdomyosarcoma</keyword>
	<keyword>metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>metastatic osteosarcoma</keyword>
	<keyword>childhood desmoplastic small round cell tumor</keyword>
	<keyword>metastatic childhood soft tissue sarcoma</keyword>
	<keyword>adult rhabdomyosarcoma</keyword>
	<keyword>recurrent adult soft tissue sarcoma</keyword>
	<keyword>stage IV adult soft tissue sarcoma</keyword>
</DOC>